KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables (2017 - 2025)

Historic Receivables for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $863.3 million.

  • BeOne Medicines' Receivables rose 5170.64% to $863.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $863.3 million, marking a year-over-year increase of 5170.64%. This contributed to the annual value of $676.3 million for FY2024, which is 8797.93% up from last year.
  • Per BeOne Medicines' latest filing, its Receivables stood at $863.3 million for Q3 2025, which was up 5170.64% from $770.8 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Receivables peaked at $863.3 million during Q3 2025, and registered a low of $80.7 million during Q2 2021.
  • In the last 5 years, BeOne Medicines' Receivables had a median value of $311.0 million in 2023 and averaged $388.3 million.
  • As far as peak fluctuations go, BeOne Medicines' Receivables skyrocketed by 56822.49% in 2021, and later plummeted by 6390.42% in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Receivables stood at $488.2 million in 2021, then crashed by 63.9% to $176.2 million in 2022, then soared by 104.17% to $359.8 million in 2023, then soared by 87.98% to $676.3 million in 2024, then grew by 27.65% to $863.3 million in 2025.
  • Its last three reported values are $863.3 million in Q3 2025, $770.8 million for Q2 2025, and $717.2 million during Q1 2025.